Toggle Offcanvas
...
 
Baricitinib Tenders

Baricitinib Tenders

View Baricitinib tenders, RFPs and contracts. Bid on readily available Baricitinib tenders with the best and most comprehensive tendering platform, since 2002.
Baricitinib is a Janus kinase JAK inhibitor used to treat rheumatoid arthritis and severe COVID 19. It works by reducing inflammation and immune response. Baricitinib has been effective in controlling autoimmune diseases but requires monitoring for infections and thrombosis risk.

Bidding for Baricitinib tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Baricitinib.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Baricitinib market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Baricitinib tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

60 Live Notices for Baricitinib Tenders

Showing 1 to 20

Completion Of Non-Exclusive Discount Agreements According To §130A (8) Sgb V On Various Active Ingredient/En/Combinations With Any Final Option Within The Framework Of The So-Called Open House Procedure
country Germany
posting date27 May 2025
deadline05 Jun 2027
Drug Supply - The Active Substance Baricitinib - Atc L04Af02
country Czech Republic
posting date29 Apr 2025
deadline30 May 2025
Open House Pharmaceutical Discounts On The Active Ingredient Baricitinib, Atc L04Af02
country Germany
posting date13 Mar 2025
deadline28 Feb 2027
Pharmaceutical Item - Rh - Ipr# 12526291, T# 22500522/Sma
country United Arab Emirates
posting date05 Mar 2025
deadline13 Dec 2025
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
country Germany
posting date16 Dec 2024
deadline04 Dec 2026

Share Share this page